Long-Term Efficacy of Baricitinib in Alopecia Areata: 3-Year Results from BRAVE-AA1 and BRAVE-AA2
September 2024
in “
Journal of the American Academy of Dermatology
”
TLDR Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
The study evaluates the long-term efficacy of baricitinib in treating severe alopecia areata over three years, focusing on patients who responded to treatment by Week 52 with a SALT score of ≤20. Results from the BRAVE-AA1 and BRAVE-AA2 trials show that 89.1% of patients on 4mg and 83.6% on 2mg maintained this level of scalp hair regrowth by Week 152. Additionally, significant improvements in eyebrow and eyelash regrowth were observed, with 80% and 66.7% of 4mg and 2mg patients, respectively, achieving notable eyebrow regrowth, and 80.9% and 78.1% achieving eyelash regrowth. These findings support the long-term use of baricitinib for maintaining hair regrowth in severe alopecia areata.